Spondylarthropathies et médicaments anti-TNFα

Conclusions. - Patients with active, severe and refractory spondylarthropathies are potential candidates for treatment with anti-TNFα drugs. Taking into account not only the efficacy but also the side effects, with rare but potentially severe complications such as tuberculosis or other opportunistic infections, and the relatively high cost of these drugs, preliminary criteria for the initiation, monitoring and discontinuation of these drugs in the treatment of spondylarthropathies were proposed. Long-term follow-up in large populations of patients with spondylarthropathies is necessary to better define the benefit/risk/cost ratio of anti-TNFα drugs.